Laser Capture Microdissection Market

The global laser capture microdissection market in terms of revenue was estimated to be worth $184 million in 2024 and is poised to reach $306 million by 2029, growing at a CAGR of 10.6% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by the rising pace of R&D and growing expenditure. On the other hand, requirement of high degree of technical expertise is a major factor restraining market growth to a certain extent.

Attractive Opportunities in Laser Capture Microdissection Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global Laser Capture Microdissection Market Dynamics

DRIVER: Increase in R&D funding

Increased R&D funding enables researchers to explore new applications for LCM across different fields. As more funding becomes available for studying complex diseases like cancer, neurodegenerative disorders, and infectious diseases, the demand for precise cell isolation techniques like LCM grows. For example, in cancer research, LCM allows for the isolation of specific tumor cells for genomic, proteomic, and transcriptomic analysis, leading to a better understanding of disease mechanisms and potential therapeutic targets. For instance, according to the Evaluate Pharma report published in August 2022, the pharmaceutical R&D expenditure across the world was estimated at around USD 256 billion in 2024, an increase of 2.6% from 2021 to 2028. The growth in the R&D expenditure by pharmaceutical and biotechnology companies, coupled with the increasing focus on life science projects for the development of new therapeutic and diagnostic products, is expected to aid the growth of the laser capture microdissection market.

RESTRAINT: Requirement of high degree of technical expertise

Technological advancements have resulted in significant improvements in laser capture microdissection. However, experts with good knowledge of laser capture microdissection as well as the skills are required for instrument and software handling. To adopt the newer technologies of this market, pharmaceutical companies and academic labs require researchers who are well versed with new techniques such as expression microdissection technique. Being a relatively new technology, expression microdissection faces a shortage of skilled and knowledgeable professionals. Due to this, companies tend to opt for microscopic techniques. All these factors make laser capture microdissection development a tedious process and thus limit its uptake among researchers. Moreover, the complexity of the instrumentation is also restraining the growth of the market as it restricts only the use by the technical expertise. Dearth of training is therefore a hurdle to the growth of the laser capture microdissection market.

OPPORTUNITY: Integration with omics technologies

LCM can be integrated with various omics technologies, such as genomics, transcriptomics, proteomics, and metabolomics, to obtain comprehensive molecular profiles of isolated cells or tissue regions. This integration enables researchers to gain insights into the molecular mechanisms underlying diseases and biological processes at a high resolution. As omics-based research continues to advance, the demand for LCM technologies that seamlessly integrate with omics workflows is expected to grow, creating opportunities for market expansion. According to the article published in the Journal of Genetics and Genomics in September 2023, conducted a study on Laser capture microdissection for biomedical research: towards high-throughput, multi-omics, and single-cell resolution, stated that LCM is highly compatible with spatially resolved multi-omics analysis, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, by dissecting samples with less contamination at single-cell resolution.

CHALLENGE: Time-consuming sample preparation process

Molecular profiling (sample preparation) in laser capture microdissection is a major challenge for the laser capture microdissection market as it is very tedious and mainly depends upon the quantity of the sample required for the further downstream processes. LCM enables differentiation between the normal and diseased cells or tissue; hence, an isolation of a particular cell should be performed keenly, which in turn is time-consuming.  Sample preparation of laser capture microdissection usually contains visualization of the cells of interest via microscope, dissection of the selected cells by the transfer of a laser energy to a thermolabile polymer with formation of a polymer-cell composite (IR system) or photo volatilization of cells surrounding a selected area (UV system), and then the capture or catapult of the cells of interest from the heterogeneous tissue section. The long and labor-intensive nature of the technique is a major challenge for the market.

Laser Capture Microdissection Industry Ecosystem

The laser capture microdissection market is a complex ecosystem involving various stakeholders, including the supply side, which includes companies providing laser capture microdissection products & services. The demand side includes academic and government research institutes, hospitals, pharmaceutical & biotechnology companies, and contract research organizations.

Several key companies provide laser capture microdissection. For example, Thermo Fisher Scientific, Inc. (US) is the leading market player. The company has maintained its leadership through its strong distribution network across Asia-Pacific, Latin America, Europe, the Middle East and Africa, and North America. It focuses on expanding its presence in the market by strategically investing in R&D to launch innovative and advanced products in the market.  Other product providers include Danaher Corporation (US), Carl Zeiss AG (Germany), F. Hoffmann-La Roche AG (Switzerland), and Standard BioTools, Inc. (US), and others.

The reagents & media sub-segment under consumables segment dominated laser capture microdissection industry by product

Laser capture microdissection is an extremely useful tool for researchers in various medical/healthcare fields. It is commonly used in hospitals & academic and government research institutes for a myriad of applications, including research and diagnostics. The use of high-performance media and reagents helps in yielding better results. Reagents are used in laser capture microdissection for tissue staining, DNA/RNA extraction & purification, RNA amplification & extraction, formalin-fixed, paraffin-embedded tissue procedures, and RNA labeling. Other important reagents include buffers, dyes, and stains. Media is often complemented with supplements such as amino acids, inorganic salts, and glucose; it is also complemented with serum for cell proliferation. Growth medium helps maintain pH and osmolality. Media is primarily used to ensure immediate survival of cells, prolonged survival of cells, and indefinite/continuous growth and specialized functions. The addition of media also enhances cell performance. In laser capture microdissection, media is mainly used to study the live cells in the samples.

The molecular biology seb-segment under research and development segment dominated laser capture microdissection industry by application

Laser capture microdissection (LCM) is a powerful technique widely utilized in molecular biology for various applications due to its ability to isolate specific cells or tissue regions from complex samples with high precision. LCM allows researchers to isolate individual cells or small groups of cells from heterogeneous tissue samples. Isolated cells can then be subjected to downstream molecular analyses at the single-cell level, including gene expression profiling, DNA sequencing, epigenetic analysis, and proteomic characterization. This enables the study of cellular heterogeneity, cell-to-cell variability, and rare cell populations within tissues. In 2022, Maastricht University published research study for Laser Capture Microdissection-Based mRNA Expression Microarrays and Single-Cell RNA Sequencing in Atherosclerosis Research.

Asia Pacific is estimated to register the highest CAGR in the laser capture microdissection industry during the forecast period.

Asia Pacific offers lucrative growth potential for the laser capture microdissection market. This can be attributed to the increasing pharmaceutical R&D spending, the growing trend of outsourcing drug discovery services, growing life sciences research, and increasing government initiatives for healthcare research. One significant growth driver for the market in the Asia Pacific region is the increasing investment in healthcare infrastructure and research & development (R&D) activities. Governments and private entities are allocating substantial funds and launching various research programs to enhance healthcare facilities and promote scientific advancements, including laser capture microdissection technologies. These investments are driving the adoption of laser capture microdissection techniques across various applications and research fields

The Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) and its Regulatory Harmonization Steering Committee (RHSC) adopted a strategic plan (Vision 2020: A Strategic Framework: Regulatory Convergence for Medical Products by 2020). This strategic plan provided the basic proposal and rationale for achieving regional regulatory convergence of medical product approval procedure. The forum’s vision is to accelerate regulatory convergence for medical products in the APEC region as much as possible by 2030 to protect people’s safety, make life-saving products available, save public resources, attract investments, mitigate corruption, and improve global standing in every APEC economy. Thus, favourable regulatory guidelines for product approval are expected to drive the market growth.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the laser capture microdissection market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Carl Zeiss AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Standard BioTools (US), JSR Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Bruker (US), Molecular Machines & Industries GmbH (Germany), Ocimum Biosolutions (US), Theralink Technologies, Inc. (US), 3DHISTECH, Ltd. (Hungary), Creative Biolabs (US), DeNova Sciences (Singapore), Laxco, Inc. (US), CaresBio Laboratory LLC (US), VitroVivo Biotech (US), AnaPath Services GmbH (Switzerland), Gnome Diagnostics & Gnome Sciences (US), Monasterium Laboratory (Germany), Independent Forensics (US), Norgen Biotek Corp. (Canada), Creative Bioarray (US), and Epistem Ltd. (UK).

Scope of the Laser Capture Microdissection Industry

This report categorizes the Laser Capture Microdissection Market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Instruments
• Consumables
  • Reagents & Media
  • Assay Kits
  • Other Consumables
• Software and services

By System Type

• Ultraviolet LCM
• Infrared LCM
• Ultraviolet and Infrared LCM
• Immunofluorescence LCM

By Application

• Research and Development
  • Molecular Biology
  • Cell biology
  • Forensic Science
• Diagnostics
• Other Applications

By End User

• Academic and government Research Institutes
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations

By Region

• North America
• US
• Canada
• Europe
• Asia Pacific (APAC)
• Rest of the World

Recent Developments of Laser Capture Microdissection Industry:

• In August 2023, Danaher Corporation (US) acquired Abcam plc (UK), a leading supplier of protein consumables. Abcam is to operate as a standalone operating company and brand within Danaher's Life Sciences segment, furthering Danaher's strategy to help map complex diseases and accelerate the drug discovery process using Danaher’s technology.
• In March 2023, Crown Bioscience International (US), a JSR Life Sciences Company, acquired a 100.0% stake in Indivumed Services GmbH& Co. KG (Germany) to further accelerate drug discovery and create solutions to meet customer needs by bringing a variety of synergistic service platforms to Crown Bioscience's drug discovery and development services.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst